Related Experiment Video
Updated: Aug 3, 2026

Automated Measurement of Microcirculatory Blood Flow Velocity in Pulmonary Metastases of Rats
Published on: November 30, 2014
Intermittent blood flow in solid tumours--an under-appreciated source of 'drug resistance'
1Department of Medical Biophysics, BC Cancer Research Centre, Vancouver, Canada. rdurand@bccancer.bc.ca
Abstract:
As the search for improved anti-cancer drugs continues, new paradigms concerning the reasons for clinical failures in common human solid tumours are also evolving. Classical drug resistance is now perhaps less often invoked to explain lack of treatment efficacy than are newer concepts, including 'contact resistance', 'tumour heterogeneity', 'regrowth resistance', and 'physiological barriers' to drug delivery. This commentary will explore the resistance of solid tumours to chemotherapy from yet another, largely ignored perspective: that of tumour-specific fluctuations in blood flow. Transient decreases in blood flow have significant implications for delivery of chemotherapeutic agents, cellular responsiveness to those agents, and the regrowth potential of the surviving tumour cells.
More Related Videos
09:00Spatial Measurements of Perfusion, Interstitial Fluid Pressure and Liposomes Accumulation in Solid Tumors
Published on: August 18, 2016
08:52Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
Published on: January 19, 2018
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistant Cancers
Drug Distribution: Tissue Binding
For...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow